RESIDENTIAL SCHOOL ON MEDICINAL CHEMISTRY:
Biology and Chemistry of Drug Discovery
Drew University, Madison, New Jersey
June 3 – 7, 2013

LECTURES
“Principles of Medicinal Chemistry”
Richard Silverman, Ph.D., Northwestern University
“Enzyme Inhibition”
Mark Namchuk, Ph.D., Vertex
“Receptor Binding Assays”
Christopher Haber, Ph.D., Pfizer
“Hit-to Lead Process in Drug Discovery”
John A. Lowe, Ph.D., JL3Pharma
“Principles of Lead Optimization”
John A. Lowe, Ph.D., JL3Pharma
“Kinase Inhibitors”
William Windsor, Ph.D., Merck
“G-Protein Coupled Receptors”
Terry Kenakin, Ph.D., UNC School of Medicine
“Drugs Affecting ION Channels”
David Triggle, Ph.D., SUNY Buffalo
“Fragment-based Drug Design”
Miles Congreve, Ph.D., Heptares Therapeutics
“Drug-like Properties in Drug Discovery”
Li Di, Ph.D., Pfizer
“Chemoinformatics”
Kent Stewart, Ph.D., AbbVie
“Drug Metabolism”
John Erve, Ph.D., Elan
“Toxic Metabolites”
John Erve, Ph.D., Elan
“Preclinical Toxicology”
James MacDonald, Ph.D., Chrysalis Pharma
“Bioisosteres”
Nicholas Meanwell, Ph.D., Bristol-Myers Squibb
“Clinical Development”
James McLeod, Ph.D., Galleon Pharmaceuticals
“Pharmacokinetics & Plasma Protein Binding”
Randy Miller, Ph.D., Merck
“Drug Design Using Structural Biology”
Vincent Stoll, Ph.D., AbbVie

CASE HISTORIES
“Suvorexant”
Paul Coleman, Ph.D., Merck
“Eltrombopag”
Kevin Duffy, Ph.D., GlaxoSmithKline
“Saxagliptin”
Jeffrey Robl, Ph.D., Bristol-Myers Squibb
“Vortioxetine”
Benny Bang-Anderson, Ph.D., Lundbeck Pharma
“Lonafarnib”
W. Robert Bishop, Ph.D., Merck ret.